9.17.02: Bear, Stearns & Co. 15th Annual Healthcare Conference Issue
Eight Analysts and top management from one hundred and thirty two sector firms examine the healthcare sector in this 472-page Bear, Stearns & Company 15th Annual Healthcare Conference Issue from The Wall Street Transcript.
  1. U.S. Pharmaceutical Companies - In an in-depth (2,900 words) Analyst Interview, Joseph P. Riccardo, a Senior Health Care Analyst & Head of the Health Care Research Group at Bear, Stearns & Co. and Scott Shevick, an analyst at Bear, Stearns & Co., examine the outlook for the sector and share specific stock recommendations.
  2. Healthcare Service Providers - In an in-depth (1,400 words) Analyst Interview, Jason Kroll, a Managing Director at Bear, Stearns & Co., examines the outlook for the sector and shares specific stock recommendations.
  3. Pharmaceutical Services - In an in-depth (2,500 words) Analyst Interview, Stephen S. Unger, Bear, Stearns & Co., examines the outlook for the sector and shares specific stock recommendations.
  4. Novel Therapeutics in Cancer & Aids - In an in-depth (2,500 words) Analyst Interview, Akhtar Samad, an Equity Research Analyst & Managing Director at Bear, Stearns & Co., examines the outlook for the sector and shares specific stock recommendations.
  5. Large Cap Biotechnology & Life Sciences - In an in-depth (4,200 words) Analyst Interview, Ronald C. Renaud, an Associate Director at Bear, Stearns & Co., examines the outlook for the sector and shares specific stock recommendations.
  6. Healthcare Distribution & Healthcare IT- In an in-depth (4,100 words) Analyst Interview, Raymond G. Falci, a Senior Managing Director at Bear, Stearns & Co., examines the outlook for the sector and shares specific stock recommendations.
  7. Outlook for Managed Care - In an in-depth (1,400 words) Analyst Interview, John Rex, a Senior Research Analyst at Bear, Stearns & Co., examines the outlook for the sector and shares specific stock recommendations.
  8. CEO interviews (average 2,500 words). Top management of 132 - sector firms examine the outlook for their firm and the sector. Firms include:
    C.R. Bard, CuraGen, Large Scale Biology, Achillion Pharmaceuticals, Actelion AG, Aetna, Agensys, AGY Therapeutics, ALARIS Medical, Albany Molecular Research, Alexion Pharmaceuticals, Allscripts, AMERIGROUP, Amicore, AstraZeneca, Biogen, Biomet, Caliper Technologies, Celgene, Edwards Lifesciences, Endocare, Genzyme Biosurgery and many more - click here to see the complete list of companies
    9. ORDER THIS REPORT NOW! ONLY $175
    The report will be mailed first class. For fedex delivery, specify in the report details section and either include your fedex number or we will add $15 delivery charge. All sales are final.  Questions, call (212) 952-7433, or email us
    For immediate access online - click here to gain a password.
     
    Report details:  
    Your Name:  
    		 Company: 
    Address: 
    		 City: 
    State/Province:
    		 ZIP/Postal Code:
          		 Country:
    Phone:
    		 E-Mail:

    BILLING INFORMATION
    Credit Card
    		 Expiration Month/Year:
    Credit Card Number: 
     

     This Issue costs $175 - and is non-returnable.   

    The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.

     

Investors and Industry Execs.

The Wall Street Transcript has been read and used by investors and industry executives for nearly 40 years. It's a vital and unique tool for doing company and industry research - as part of a stock purchase decision or as part of a market analysis.

Investors:
TWST's roundtable panels and analyst interviews provide a sector perspective from Wall Street's best. Find out where they agree, and where they disagree on stock recommendations. Money manager interviews provide the view from the buy-side. And CEO interviews with hundreds of companies from the major sectors gives the company perspective right from the top.

Industry Executives:
Get the insider view on the sector from Wall Street Analysts and Company CEO's. Company strategies, growth ambitions, new products and markets, management - these and much more are discussed by the top executives in the industry. TWST's reports should be a key part of any industry research.

Subscribe to a unique research tool for investors and industry executives. Call (212) 952 7433 or click here.

Sincerely,

Andrew Pickup
Publisher
HOME PRODUCTS SUBSCRIBE ABOUT ARCHIVE HOTLINE CONTACT EUROPE